Clinical trial patient recruitment that fills your studies with qualified participants.

The FDA treats advertising for study participants as the start of informed consent, so its guidance expects the IRB to review recruitment materials before they're used. That covers ads, study pages, pre-screener wording and even the scripts staff use on follow-up calls.

A partner who drafts copy first and asks about approval later costs you weeks. We write every piece with the review in mind: no promises of a cure or of benefit, no wording that plays down risk, compensation stated plainly rather than as the headline, and the study described in words a participant would use.

We send your team a single approval packet with every ad, page and question in one place, and nothing goes live until it comes back approved. When a protocol amendment changes the criteria, the screener and pages change with it and go back through review.

Most recruitment waste happens after the click. A campaign that brings in hundreds of sign-ups looks busy, but if most of them fail on age, diagnosis or a medication they're already taking, your coordinators spend days on calls that go nowhere and the real candidates wait.

A short pre-screener, built from the handful of criteria that rule out the most people, fixes that. It filters before a person ever reaches your team, it tells people who don't qualify kindly and right away, and it hands coordinators a list worth calling.

Speed matters just as much. Someone who signs up for a study is often ready that day and much less interested three days later, so qualified leads should get a call or text within minutes during working hours and first thing the next morning otherwise.

Then the numbers that matter are screen visits and randomizations, not form fills.

A person who answers a pre-screener is telling you about their health, and that information has no place in an ad platform or an analytics dashboard. Our setup keeps the two apart.

Ad and analytics tools see that someone visited a page or finished the form, never their answers. Screener responses go to your team through secure forms and hosting, and we sign a business associate agreement wherever patient information is involved.

Tracking still reports what you need: which channel, which ad and which study produced each screen visit and each randomized patient. Your regulatory lead gets a written description of how data moves, what is collected and where it is stored, so they can check it against your site's policies and the sponsor's requirements before launch, rather than after a question comes up during monitoring.